Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329560 · ClinicalTrials.gov registry record · Phase 1
Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV
A Phase 1 study of HIV-1-infection, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03329560 is a Phase 1 study of HIV-1-infection that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 6 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03329560, a Phase 1 study of HIV-1-infection, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether oral fecal microbiota transplantation (FMT) is safe for people with human immunodeficiency virus (HIV) infection.
Conditions Studied
Interventions
- BIOLOGICAL Oral fecal microbiota transplantation
Study Locations (1)
Texas
- Thomas Street Health Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2019-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03329560
The ClinicalTrials.gov registry entry for NCT03329560 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (98% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Oral fecal microbiota transplantation is the first listed.
NCT03329560 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03329560 about?
NCT03329560 is a clinical study titled "Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV". The purpose of this study is to determine whether oral fecal microbiota transplantation (FMT) is safe for people with human immunodeficiency virus (HIV) infection.
What is the current status of trial NCT03329560?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-04-12. Estimated completion is 2019-10-08.
What conditions does trial NCT03329560 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT03329560?
The interventions under investigation include: Oral fecal microbiota transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03329560?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03329560 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
RECRUITING · Phase 1
-
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
RECRUITING · Phase 1
-
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
RECRUITING · Phase 1
-
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
RECRUITING · Phase 1
-
Safety Study of MucoCept-CVN
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.